Enhancing Functional Recovery in Stroke Survivors: An Observational Study on the Effectiveness of Argigold Max Supplementation in Rehabilitation

A BSTRACT Introduction: Stroke is a major cause of death and disability globally, with significant functional and cognitive impairments affecting survivors. Rehabilitation strategies are crucial in improving functional outcomes such as muscle strength, cognitive function, and activities of daily living (ADL). This study evaluates the effectiveness of Argigold Max supplementation in improving functional recovery in stroke patients. Materials and Methods: This observational study involved 218 poststroke patients who received Argigold Max supplementation once daily for 3 months, alongside a standard rehabilitation program. Functional outcomes were assessed using the manual muscle testing (MMT) scale for muscle strength, the brief interview for mental status (BIMS) for cognitive function, and the Barthel index (BI) for ADL. Ethics approval was obtained from the Independent Ethics Committee (Study number 01/2024). Descriptive statistics and paired t -tests were used for data analysis. Results: Significant improvements were observed in all measured parameters after Argigold Max supplementation for 3 months. The MMT scores showed a marked increase from a baseline mean of 2.29 ± 0.47–3.48 ± 0.54 ( P < 0.0001). Cognitive function, assessed by BIMS, improved significantly from a baseline mean of 8.23 ± 2.74–12.44 ± 2.04 ( P < 0.0001). The BI scores also demonstrated improvement (18.17 ± 2.24–92.71 ± 1.68), indicating better ADL independence. Global assessments revealed 98.3% of patients reporting improved or very much improved health status. Furthermore, 98.4% expressed satisfaction with the Argigold Max treatment. Conclusion: This study suggests that Argigold Max supplementation with standard rehabilitation significantly improves muscle strength, cognitive function, and ADL performance in stroke patients, supporting its role in enhancing recovery and quality of life.